Yes. Preclinical MRI is a powerful tool to assess brain atrophy in the ΔNLS model. Non-invasive anatomical MR imaging allows for longitudinal measures of regional brain volume and cortical thickness, and can serve as a sensitive, clinically-translational biomarker of potential disease modification via therapeutic intervention.